Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Taiwan ETF (EWT) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI Taiwan ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Taiwan ETF vs Eli Lilly And Co — how do they compare? iShares MSCI Taiwan ETF trades at $100.7, while Eli Lilly And Co trades at $1,176.27 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while iShares MSCI Taiwan ETF pays none. Which is the better fit depends on your goals.

EWTLLY
Sector
Broad Market / FactorHealth
52-Week High
$111.53$1.24K
52-Week Low
$58.05$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Taiwan ETF

EWT (iShares MSCI Taiwan ETF) trades at $100.60, down 1.26% on the day amid neutral technical signals. The ETF has delivered exceptional performance with a 100%+ gain in 2026, driven by Taiwan's dominant semiconductor sector and AI infrastructure exposure. Current technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support levels cluster around $99-$101.

The outlook remains favorable given Taiwan's critical role in global semiconductor supply chains and AI infrastructure growth, though stretched valuations and geopolitical tensions with China present significant risks. Institutional interest remains strong due to concentrated exposure to TSMC and other tech leaders, but investors should monitor dollar movements and regional stability.

Eli Lilly And Co

LLY trades at $1,154.27, down 2.6% today, amid a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $8.55 surpassing the $6.97 forecast. Revenue surged to $65.18B in 2025, driving a net income margin of 34.99%. Recent news includes the acquisition of AtaiBeckley for $2.8 billion, expanding its neuroscience pipeline.

Outlook remains positive with a consensus price target of $1,380, though high valuation multiples (P/E 41.09) and competitive pressures in obesity drugs present risks. Analyst sentiment is strongly bullish (73% buy ratings), supporting further upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Taiwan ETF

EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.

Read more on EWT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY